Emmecell
Seong Son is an accomplished finance professional with extensive experience in financial leadership and corporate development across various industries. Currently a Consultant at Emmecell since October 2023, Seong previously served as Head of Global FP&A at Avellino Lab, where responsibilities included scaling finance operations for public company readiness. Notable roles also include Director of Global Corporate Development at Rakuten Medical, driving financial modeling for licensing and M&A decisions, and leading FP&A initiatives at Ximedica and Lumenis, where strategic planning and process improvements enhanced profitability and operational efficiency. Seong holds an MBA in Finance from USC Marshall School of Business and a BS in Applied Economics from the University of California, Berkeley.
This person is not in any teams
Emmecell
Emmetrope Ophthalmics LLC, (aka “Emmecell”) is a privately-held, clinical stage biotechnology company developing cell-based therapies. Emmecell’s platform technology leverages magnetic nanoparticles to effectively localize and integrate cell therapies to the appropriate target tissue. Our lead product EO2002 is a cell therapy for treatment for corneal edema, the most common indication for corneal transplantation. Cell Manufacturing and Production LLC (CellMP) was founded in 2018 and is a subsidiary of Emmecell providing GMP manufacturing services in Menlo Park, CA.